Faster global financial news!
Bristol-Myers Squibb
-
Bristol-Myers Squibb Company(BMY) Q3: EPS 1.35 USD (above forecast), Revenue 13.07B USD (above forecast)
Bristol-Myers Squibb Company(BMY) Q3 EPS: 1.35 USD; Forecast 1.1 USD Revenue: 13.07B USD; Forecast 12.72B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-29
-
Yahoo Finance Analysis: Bristol Myers Squibb (BMY) is a solid buy among healthcare stocks, with a forward yield nearing 4%, as patent cliff fears are deemed overblown.
The analysis notes that despite a major patent cliff, with Eliquis and Opdivo losing U.S. patent exclusivity in 2028, Bristol Myers Squibb's stock appears cheap at under 10 times forward earnings. Ana
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Morgan Stanley maintained an "Underweight" rating on Bristol Myers Squibb (BMY) with a price target of $40, significantly below the current share price, due to patent expiration risks and delays in new drug development.
Despite Bristol Myers Squibb's strong second-quarter results and an upward revision to its full-year 2026 revenue forecast, Morgan Stanley reiterated its "Underweight" rating and a price target of $40
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
-
Bristol-Myers Squibb Company(BMY) Q3: EPS 1.35 USD (above forecast), Revenue 13.07B USD (above forecast)
Bristol-Myers Squibb Company(BMY) Q3 EPS: 1.35 USD; Forecast 1.1 USD Revenue: 13.07B USD; Forecast 12.72B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-29
-
Yahoo Finance Analysis: Bristol Myers Squibb (BMY) is a solid buy among healthcare stocks, with a forward yield nearing 4%, as patent cliff fears are deemed overblown.
The analysis notes that despite a major patent cliff, with Eliquis and Opdivo losing U.S. patent exclusivity in 2028, Bristol Myers Squibb's stock appears cheap at under 10 times forward earnings. Ana
-
LB Pharmaceuticals (LBRX) IPO Stock Has Tripled In Under A Year, Prompting Speculation It Could Be A Takeover Target
The small biotech company, which is based in New York, has one drug called LB-102, an oral formulation of the antipsychotic benzamide, and is working to challenge Bristol Myers Squibb (BMY) and Johnso
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Morgan Stanley maintained an "Underweight" rating on Bristol Myers Squibb (BMY) with a price target of $40, significantly below the current share price, due to patent expiration risks and delays in new drug development.
Despite Bristol Myers Squibb's strong second-quarter results and an upward revision to its full-year 2026 revenue forecast, Morgan Stanley reiterated its "Underweight" rating and a price target of $40
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
- No data
Bristol-Myers Squibb
24H Trending
-
1
WTWOOL Coin Trading Guide: Understanding How to Buy and Sell Wolf Town Wool Tokens and Their Exchange Listings
-
2
OneKey founder Yishi warns: Some older iPhone models have unfixable chip vulnerabilities, endangering seed phrase storage security.
-
3
XRP Long/Short Critical Point: The Battle to Defend the $1.30 Support and the Resurgence of ETF Expectations
-
4
A List of Major Global Bitcoin Exchanges
-
5
EBEN Token: Green Ben Token Analysis and Market Status
-
6
SHKG (Shikage) Analysis: Current Status of Rug-Pull Prevention Liquidity Locking Project
-
7
SK Hynix held its first "Partner Day" in Japan, deepening cooperation with over 20 Japanese semiconductor suppliers to strengthen the chip supply chain.
-
8
Pakistan refineries report 1,860% profit surge for Q3
-
9
Quant Network (QNT) Token Analysis: Interoperability, Applications, and Market Outlook
-
10
CAKE Token: Initial Price and Current RMB Value Analysis
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
